This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taulli, R. Articles by Ponzetto, C. Search for Related Content PubMed PubMed Citation Articles by Taulli, R. Articles by Ponzetto, C.

Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma

¹ Center for Experimental Research and Medical Studies (CERMS), ² Department of Anatomy, Pharmacology and Forensic Medicine, and ³ Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy

Requests for reprints: Carola Ponzetto, Department of Anatomy, Pharmacology, and Forensic Medicine, University of Turin, C.so Massimo d'Azeglio 52, 10126 Turin, Italy. Phone: 39-011-670-7747; Fax: 011-39-011-670-7732; E-mail: carola.ponzetto{at}unito.it.

Rhabdomyosarcoma (RMS) is a highly malignant soft-tissue tumor of childhood deriving from skeletal muscle cells. RMS can be classified in two major histologic subtypes: embryonal (ERMS) and alveolar (ARMS), the latter being characterized by the PAX3/7-FKHR translocation. Here we first investigated whether the Met receptor, a transcriptional target of PAX3 and PAX7, has a role in PAX3-FKHR–mediated transformation. Following PAX3-FKHR transduction, Met was up-regulated in mouse embryonal fibroblasts (MEF), NIH 3T3 and C2C12 cells, and they all acquired anchorage independence. This property was lost in low serum but addition of hepatocyte growth factor/scatter factor (HGF/SF) rescued soft-agar growth. Genetic proof that Met is necessary for this PAX3-FKHR–mediated effect was obtained by transducing with PAX3-FKHR MEFs derived from Met mutant (Met^D/D) and wild-type (Met^+/+) embryos. Only Met^+/+ MEFs acquired anchorage-independent growth whereas PAX3-FKHR–transduced Met^D/D cells were unable to form colonies in soft agar. To verify if Met had a role in RMS maintenance, we silenced the receptor by transducing ERMS and ARMS cell lines with an inducible lentivirus expressing an anti-Met short hairpin RNA (shRNA). Met down-regulation significantly affected RMS cells proliferation, survival, invasiveness, and anchorage-independent growth. Finally, induction of the Met-directed shRNA promoted a dramatic reduction of tumor mass in a xenograft model of RMS. Our data show that both ARMS- and ERMS-derived cell lines, in spite of the genetic drift which may have occurred in years of culture, seem to have retained an "addiction" to the Met oncogene and suggest that Met may represent a target of choice to develop novel therapeutic strategies for ARMS. (Cancer Res 2006; 66(9): 4742-9)

This article has been cited by other articles:

				D. Yan, X. D. Dong, X. Chen, L. Wang, C. Lu, J. Wang, J. Qu, and L. Tu MicroRNA-1/206 Targets c-Met and Inhibits Rhabdomyosarcoma Development J. Biol. Chem., October 23, 2009; 284(43): 29596 - 29604. [Abstract] [Full Text] [PDF]

				S. Oesch, D. Walter, M. Wachtel, K. Pretre, M. Salazar, M. Guzman, G. Velasco, and B. W. Schafer Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma Mol. Cancer Ther., July 1, 2009; 8(7): 1838 - 1845. [Abstract] [Full Text] [PDF]

				J. Kucharczak, S. Charrasse, F. Comunale, J. Zappulla, B. Robert, I. Teulon-Navarro, A. Pelegrin, and C. Gauthier-Rouviere R-Cadherin Expression Inhibits Myogenesis and Induces Myoblast Transformation via Rac1 GTPase Cancer Res., August 15, 2008; 68(16): 6559 - 6568. [Abstract] [Full Text] [PDF]

				S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2) J. Biol. Chem., June 27, 2008; 283(26): 18158 - 18166. [Abstract] [Full Text] [PDF]

				Y. Guo, J. Xie, E. Rubin, Y.-X. Tang, F. Lin, X. Zi, and B. H. Hoang Frzb, a Secreted Wnt Antagonist, Decreases Growth and Invasiveness of Fibrosarcoma Cells Associated with Inhibition of Met Signaling Cancer Res., May 1, 2008; 68(9): 3350 - 3360. [Abstract] [Full Text] [PDF]

				W. Roeb, A. Boyer, W. K. Cavenee, and K. C. Arden PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1 PNAS, November 13, 2007; 104(46): 18085 - 18090. [Abstract] [Full Text] [PDF]

				O. Slater and J. Shipley Clinical relevance of molecular genetics to paediatric sarcomas J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194. [Abstract] [Full Text] [PDF]

				T. Crepaldi, F. Bersani, C. Scuoppo, P. Accornero, C. Prunotto, R. Taulli, P. E. Forni, C. Leo, R. Chiarle, J. Griffiths, et al. Conditional Activation of MET in Differentiated Skeletal Muscle Induces Atrophy J. Biol. Chem., March 2, 2007; 282(9): 6812 - 6822. [Abstract] [Full Text] [PDF]

				M. Tsuda, I. J. Davis, P. Argani, N. Shukla, G. G. McGill, M. Nagai, T. Saito, M. Lae, D. E. Fisher, and M. Ladanyi TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition Cancer Res., February 1, 2007; 67(3): 919 - 929. [Abstract] [Full Text] [PDF]

				D. Grimm and M. A. Kay RNAi and Gene Therapy: A Mutual Attraction Hematology, January 1, 2007; 2007(1): 473 - 481. [Abstract] [Full Text] [PDF]

				S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]